Inicio
Este sitio está destinado a profesionales de la salud.

Guía sobre la fibrosis pulmonar, módulo 4: La conversación difícil

Compartir

Descripción

Esta actividad cuenta con el apoyo de una subvención educativa independiente de BMS. Este programa educativo en línea se ha diseñado para profesionales sanitarios de todo el mundo, excepto del Reino Unido.

Únase al experto Dr. Fernando Martínez para obtener una guía práctica sobre cómo integrar la planificación proactiva de los cuidados (ACP) en el tratamiento a largo plazo de la enfermedad pulmonar intersticial (EPI). En esta sesión se analiza cómo ciertos factores clínicos objetivos, como el deterioro funcional y el estadio ILD-GAP, indican la necesidad de iniciar conversaciones sobre los cuidados de apoyo de forma paralela al tratamiento modificador de la enfermedad.

Este es el módulo cuatro de cuatro. Los módulos uno, dos y tres se pueden consultar aquí.

Puntos destacados de la sesión

  • Inicie las conversaciones sobre la planificación de los cuidados con antelación, utilizando parámetros clínicos objetivos como el estadio ILD-GAP y el deterioro funcional, en lugar de esperar a que se produzcan crisis agudas.
  • Aplicar estrategias de comunicación empáticas y centradas en el paciente que aclaren las preferencias asistenciales, los objetivos del tratamiento y los límites de la escalada de cuidados sin utilizar jerga médica.
  • Integrar las vías de cuidados de apoyo y paliativos en paralelo con las terapias antifibróticas en curso para mantener la calidad de vida del paciente.
  • Documentar las decisiones sobre la planificación anticipada de la atención directamente en paneles de control compartidos para mantener una visibilidad multidisciplinar clara y la continuidad de la atención.

Público destinatario

Esta actividad está dirigida a neumólogos, reumatólogos, radiólogos torácicos, patólogos, enfermeros especializados en neumología y auxiliares médicos que desempeñan un papel fundamental en el diagnóstico y el tratamiento de la FPI y la FPP. También está diseñada para médicos de cabecera, terapeutas respiratorios, farmacéuticos y otros profesionales sanitarios multidisciplinares implicados en la atención a pacientes con fibrosis pulmonar.

Profesorado

El Dr. Fernando Martínez es catedrático de la División de Medicina Pulmonar y director interino del Departamento de Medicina de la Facultad de Medicina Chan de la Universidad de Massachusetts, en Worcester (Massachusetts). Titulado en Medicina y con un máster en Ciencias, es un destacado clínico e investigador con una larga trayectoria dedicada a la medicina académica, la atención al paciente y las estrategias multidisciplinares en medicina respiratoria.

Declaraciones de intereses

De conformidad con las directrices de EBAC®, todos los ponentes y moderadores que participan en este programa han declarado o señalado cualquier posible conflicto de intereses que pudiera sesgar sus presentaciones. El Comité Organizador o el director del curso es responsable de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a los asistentes antes del inicio de las actividades de formación continua.

El Dr. Fernando Martínez, ponente de esta actividad, ha declarado haber mantenido relaciones financieras en los últimos 36 meses con las siguientes empresas no elegibles: asesor de Lung Therapeutics; consultor, asesor y ponente de Boehringer Ingelheim y Chiesi; miembro del Comité de Supervisión de Datos y Seguridad (DSMB) de Pliant; investigador de AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro y Vicore.

El personal de MedAll, así como los organizadores y revisores, no tienen relaciones financieras relevantes con empresas no elegibles que deban revelarse.

Información sobre la formación médica continua (FMC) de EBAC®:

Esta actividad se ha planificado y llevado a cabo de conformidad con los requisitos y políticas de acreditación de la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC).

MedAll es un proveedor acreditado por la EBAC desde 2025. La Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC) acredita programas de formación continua (FC) para la comunidad médica internacional.

Este programa está acreditado por la Junta Europea para la Acreditación de la Formación Continua de los Profesionales de la Salud (EBAC®) con 15 minutos de tiempo efectivo de formación.

De conformidad con las directrices de la EBAC, todos los ponentes y moderadores que participan en este programa han revelado o señalado posibles conflictos de intereses que podrían dar lugar a un sesgo en las presentaciones. El Comité Organizador y el director del curso son responsables de garantizar que todos los posibles conflictos de intereses relevantes para el evento se comuniquen a los asistentes antes del inicio de las actividades de formación continua.

La EBAC® mantiene un acuerdo de reconocimiento mutuo de equivalencia sustantiva con el Consejo de Acreditación de Estados Unidos para la Formación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá, respectivamente.

Mediante un acuerdo entre la Junta Europea de Acreditación de la Formación Continua para Profesionales de la Salud (EBAC®) y la Asociación Médica Americana (AMA), los médicos pueden convertir los créditos de formación médica continua externa de la EBAC® en créditos AMA PRA de categoría 1. La información sobre el proceso para convertir créditos EBAC® en créditos AMA se puede consultar en la página web de la AMA. Otros profesionales sanitarios pueden obtener de la AMA un certificado de participación en una actividad que da derecho a la conversión de créditos en créditos AMA PRA de categoría 1.

El Consejo de Acreditación para la Educación Médica Continua (ACCME) y el Colegio Real de Médicos y Cirujanos de Canadá mantienen un acuerdo de equivalencia sustantiva de los sistemas de acreditación con EBAC.

EBAC® es miembro de la Academia Internacional para la Acreditación del Desarrollo Profesional Continuo (IACPDA) y miembro asociado de la Asociación Internacional de Autoridades Reguladoras Médicas (IAMRA).

Cómo obtener su crédito de formación médica continua (FMC) de EBAC®:

Para obtener su crédito de FMC y recibir su certificado, participe en la actividad y complete la evaluación al final. Recibirá un enlace a su certificado tras completar la evaluación.

Costes de participación

La participación en este programa es gratuita.

Esta actividad de formación continua estará activa a partir del 1 de noviembre de 2026 y caducará el 30 de septiembre de 2027.

Tiempo estimado para completar esta actividad: 15 minutos

Objetivos de aprendizaje

Al finalizar esta actividad, los participantes serán capaces de:

  • Incorporar la estratificación del riesgo, las técnicas de imagen de alta resolución y la evaluación multidisciplinar para diferenciar y diagnosticar la FPI y la FPP de otras enfermedades pulmonares intersticiales de forma precoz y precisa.
  • Poner en práctica estrategias multidisciplinares de diagnóstico y tratamiento para mejorar la detección oportuna, la derivación y la atención coordinada de los pacientes con FPI.
  • Aplicar los conocimientos sobre los mecanismos de acción y la evidencia clínica a las decisiones terapéuticas, incluyendo la selección de pacientes y el momento adecuado para iniciar el tratamiento.

Comunidades similares

Ver todo

Eventos y vídeos bajo demanda similares

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So here we are 18 months later, um, we're trying to impress upon you the value of having some type of a dashboard that would give you sort of hints during the management of the patient. This is now a new kind of flag, and it wasn't that one that's not necessarily related to any specific medication, because here you are sitting with Margaret, you've heard her little uh components there. Uh, and over the last 18 months, you know that she's had an elevated gap score, so she's at advanced risk for progression. And sure enough, the lung function parameters demonstrate that her forced vital capacity has been steadily going downhill. Her DLCO is pretty poopy, and most of Importantly, she's noticing it. She is now not able to do the same as she was doing before. She's can't go up a flight of stairs, uh, she can't go up a hill, uh, and so part of what we want you to understand within the concept of this sort of holistic multidisciplinary approach is to have a sense that this person is at risk and has had functional decline, but there's been no documentation of uh advanced care approaches. And so here we are, 18 months of monitoring her going downhill, and no one's addressed this conversation. So, the question here is the gap, and by this, I don't mean ILD gap, but I mean the gap in her care, isn't really her numbers, it's that we haven't done a good job in providing this care. And so this is part of what we want to try to impress upon you the importance of looking at something like, so this is your hypothetical, uh, dashboard, and what you're looking at is, OK, there's a little Warning on Margaret, uh, who's got, uh, rheumatoid arthritis and associated ILD. She's had an elevated gap stage, so sort of physiologically and clinically, we know she's at risk. In fact, we've documented that there's progression in her pulmonary functions, and she's symptomatically noticing it. And when we look at our, our concepts of advanced uh care planning, That there's just no clear documentation that we've addressed, uh, what she wants, uh, how she wants to be managed, goals of care, place of care, what she wants to do therapeutically and non-ph pharmaco therapeutically for sort of escalation preferences, and there's no evidence that there's been any advanced care planning in her record. Uh, and I think that, that's where we want. To adjust ourselves, our practice pattern, to avoid this gap in care, which is to address the progressive nature of this disorder. So here we come back to, um, to Margaret. Uh, we, we've got a clinician who's talking with her, uh, and, and I want you to sort of to, to look at the way this interaction takes place, uh, and think about it if this were you, uh, what was good. What was that good? What could have been done better? What tools could I have used to better support this, uh, discussion and, and see what, how you guys would, would, would manage this, uh, in, uh, in Margaret's case. Margaret, good to see you. So your numbers, the breathing test has dropped again, and your gap stage is now a 2, which does change the trajectory conversation. I noticed there's no advanced care planning documentation on file, so we should really get that sorted today. It's just a form, nothing to worry about, a form. Is this because it's getting worse? Well, the decline does meet, um, progression thresholds, but let's not get ahead of ourselves. Basically, we document your preferences, resuscitation, escalation, that kind of thing. So it's all on file. Some people involve family, that's an option. Does that sound OK? I suppose. I'd have to think. Great. Reception can print the paperwork and we'll pick it up at your next visit. You're doing really well, all things considered. Right Thank you, doctor. I'll tell you my impression was that this was, you know, it was a well meant discussion, but it was kind of a little bit rushed and a lot of jargon that was being used, um, and as we come back to trying to get a sense of proactive care, using a dashboard like we've sort of presented for you to, to highlight for us, understand we've got an at-risk person, because, you know, there, there's already a, a methodology that's been introduced to identify high-risk individuals. In this case, you, you know that she's at risk. Uh, as you progress in parallel, you're treating, you're monitoring, in her case, you saw her lung function going in that direction, and, and so you're supporting her with management of whatever therapeutic approach you've taken. At the same time, we wanna have you be able to understand in a person like Margaret. It's important to be able to be proactive in asking, what do you wanna do? What matters to you? What, what are your goals, uh, Margaret? Um, how do you wanna achieve those? Do you wanna do it pharmacologically, non-pharmacologically? Uh, do you wanna do it here or you wanna do it in a different location? And all of that has to be documented so that all of your colleagues that are involved in her care get a good sense of, of this approach to proactive management from the earliest stage of disease. To what we do as the stage progresses in appropriately establishing goals, plans, and maximizing satisfaction for all involved, particularly Margaret. Uh, and so this advanced care planning is not really the end of treatment. It's sort of like a safety rail that runs in parallel to, to maximize the outcomes that occur. So if, if I were gonna take away my impressions from, from this, uh, this presentation, the goal of what we're trying to achieve is that advanced care planning is longitudinal. It is, it's not dealing with whenever there's a crisis, uh, it is something that's based on the, the baseline assessment and then a very careful discussion with the patient of what the patient wants. Where she wants to do the care and, and what she wants as her ultimate goals, that, that same dashboard that guards adherence should aid you in management the conversation. This documentation of those discussions in your advanced care plan is gonna be useful for you, for Margaret, and for any other clinician that's involved in her care. And, and the idea of being supportive and being able to provide disease modifying therapy which we now have sort of runs in parallel. That, that's an, an advantage for you. It's an advantage most importantly for the patient. And so neither of those cancels the other. They're this joint uh care. I warned you this was coming again. So here's your poll. Again, the same question we asked earlier, how confident are you that you would recognize and act on early ILD management in a patient like Margaret? Same options from not at all confident all the way to completely confident. Uh, and so let's see how that's changed over the course of the last hour. All right. Here we come back to Margaret. Uh, so you, you know, gone through the diagnosis. Um, we, we've sort of asked Margaret, OK, listen, what do you think, uh, you would have wanted, uh, to have happened earlier? You, from the patient's point of view, it was important insight. What's your stance, Margaret? Let's see what she says. I don't think anyone did anything wrong, exactly, but my care team knew my lungs could be affected. I didn't. I wish that had been checked before I could feel anything, and I wish someone had clearly overseen the results and the conversation about what matters to me. I'd have been ready for that much earlier than anyone asked. All right. So, most importantly, when you participate in a program like this, to try to remember at least one thing that, that you're going to do differently. Uh, and so these are, these are potentially options, uh, for you to consider. It's most importantly for you and your practice setting. Uh, know what a risk profile looks like, um, so that you, you're establishing some thoughts regarding how you want to interact with Margaret before any symptoms occur, certainly before there's any crisis that's occurred. Uh, put that as a flag to yourself and act on that, uh, when you have an opportunity, um, give every flag an owner, so whenever you're documenting these components, in particularly if you have structured reports, which always simplify things, make sure that there's good documentation that you address these components of the advanced care planning. So that the multidisciplinary discussion, which is the gold standard for all of us in diagnosis and management, becomes part of the routine for all clinicians that are involved with managing Margaret during the course of her, of her journey, uh, and then, you know, treat tolerability as a treatment. You know, all of these drugs have challenging components, some less, some more. Be proactive in managing some of the particularly GI side effects with the patient. There is a, a, a broad, it's amazing the, the level of advance we've made in therapy and it's continuing to proceed. So, so Margaret's gonna have a lot of options, and so you're gonna have to really be able to document all of that, make sure that you've had those discussions with Margaret, they're recorded in your, in your action plan, and you close the loop with the patient. Because what, what's most important is what matters to her during the course of this longitudinal journey with you and aiding her with her care.